BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Behary J, Amorim N, Jiang XT, Raposo A, Gong L, McGovern E, Ibrahim R, Chu F, Stephens C, Jebeili H, Fragomeli V, Koay YC, Jackson M, O'Sullivan J, Weltman M, McCaughan G, El-Omar E, Zekry A. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat Commun 2021;12:187. [PMID: 33420074 DOI: 10.1038/s41467-020-20422-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu J, Zhan Q, Fan Y, Lo EKK, Zhang F, Yu Y, El-Nezami H, Zeng Z. Clinical Aspects of Gut Microbiota in Hepatocellular Carcinoma Management. Pathogens 2021;10:782. [PMID: 34206200 DOI: 10.3390/pathogens10070782] [Reference Citation Analysis]
2 Nakatsu G. Toward a postbiotic era of microbiome science: Opportunities to advance immunotherapies for hepatocellular carcinoma. J Gastroenterol Hepatol 2021. [PMID: 34665475 DOI: 10.1111/jgh.15715] [Reference Citation Analysis]
3 Mao X, Peng X, Pan Q, Zhao X, Yu Z, Xu D. Uterine Fibroid Patients Reveal Alterations in the Gut Microbiome. Front Cell Infect Microbiol 2022;12:863594. [DOI: 10.3389/fcimb.2022.863594] [Reference Citation Analysis]
4 Zhang C, Franklin CL, Ericsson AC. Consideration of Gut Microbiome in Murine Models of Diseases. Microorganisms 2021;9:1062. [PMID: 34068994 DOI: 10.3390/microorganisms9051062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhang N, Gou Y, Liang S, Chen N, Liu Y, He Q, Zhang J. Dysbiosis of Gut Microbiota Promotes Hepatocellular Carcinoma Progression by Regulating the Immune Response. J Immunol Res 2021;2021:4973589. [PMID: 34722779 DOI: 10.1155/2021/4973589] [Reference Citation Analysis]
6 Shih MK, Tain YL, Cheng CM, Hsu CN, Chen YW, Huang HT, Chang CI, Hou CY. Separation and Identification of Resveratrol Butyrate Ester Complexes and Their Bioactivity in HepG2 Cell Models. Int J Mol Sci 2021;22:13539. [PMID: 34948341 DOI: 10.3390/ijms222413539] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zhang C, Yang M. Targeting T Cell Subtypes for NAFLD and NAFLD-Related HCC Treatment: An Opinion. Front Med (Lausanne) 2021;8:789859. [PMID: 34869507 DOI: 10.3389/fmed.2021.789859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Hu S, Luo L, Bian X, Liu RH, Zhao S, Chen Y, Sun K, Jiang J, Liu Z, Zeng L. Pu-erh Tea Restored Circadian Rhythm Disruption by Regulating Tryptophan Metabolism. J Agric Food Chem 2022. [PMID: 35475616 DOI: 10.1021/acs.jafc.2c01883] [Reference Citation Analysis]
9 Bruneau A, Hundertmark J, Guillot A, Tacke F. Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases. Front Med (Lausanne) 2021;8:725390. [PMID: 34650994 DOI: 10.3389/fmed.2021.725390] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Gupta H, Min B, Ganesan R, Gebru YA, Sharma SP, Park E, Won S, Jeong J, Lee S, Cha M, Kwon G, Jeong M, Hyun J, Eom J, Park H, Yoon S, Choi M, Kim D, Suk K. Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role. Biomedicines 2022;10:550. [DOI: 10.3390/biomedicines10030550] [Reference Citation Analysis]
11 Montella L, Sarno F, Ambrosino A, Facchini S, D'Antò M, Laterza MM, Fasano M, Quarata E, Ranucci RAN, Altucci L, Berretta M, Facchini G. The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma. Cells 2021;10:1909. [PMID: 34440678 DOI: 10.3390/cells10081909] [Reference Citation Analysis]
12 Jiang X, Xu Y, Chen D, Wang M, Qiu M, Xiong L, Zhang L, Yu H, Xiong Z. A Novel Angiogenesis-Related Prognostic Signature Associated with the Hepatocellular Carcinoma Immune Microenvironment and Survival Outcome. Int J Gen Med 2022;15:311-23. [PMID: 35027841 DOI: 10.2147/IJGM.S349210] [Reference Citation Analysis]
13 Qi X, Zhang L, Xu J, Tao Z, Wang X, Qiu Y, Pan T, Liu Z, Qu H, Tan R, Liu J. Association of Increased Circulating Acetic Acid With Poor Survival in Pseudomonas aeruginosa Ventilator-Associated Pneumonia Patients. Front Cell Infect Microbiol 2021;11:669409. [PMID: 33996639 DOI: 10.3389/fcimb.2021.669409] [Reference Citation Analysis]
14 Giraud J, Saleh M. Host-Microbiota Interactions in Liver Inflammation and Cancer. Cancers (Basel) 2021;13:4342. [PMID: 34503151 DOI: 10.3390/cancers13174342] [Reference Citation Analysis]
15 Pomej K, Balcar L, Scheiner B, Semmler G, Meischl T, Mandorfer M, Reiberger T, Müller C, Trauner M, Pinter M. Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib. J Hepatocell Carcinoma 2021;8:1485-93. [PMID: 34877268 DOI: 10.2147/JHC.S317957] [Reference Citation Analysis]
16 Wang H, Wang Q, Yang C, Guo M, Cui X, Jing Z, Liu Y, Qiao W, Qi H, Zhang H, Zhang X, Zhao N, Zhang M, Chen M, Zhang S, Xu H, Zhao L, Qiao M, Wu Z. Bacteroides acidifaciens in the gut plays a protective role against CD95-mediated liver injury. Gut Microbes 2022;14:2027853. [DOI: 10.1080/19490976.2022.2027853] [Reference Citation Analysis]
17 Bartolini I, Risaliti M, Tucci R, Muiesan P, Ringressi MN, Taddei A, Amedei A. Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment. World J Gastrointest Oncol 2021; 13(11): 1616-1631 [PMID: 34853639 DOI: 10.4251/wjgo.v13.i11.1616] [Reference Citation Analysis]
18 Paternostro R, Sieghart W, Trauner M, Pinter M. Cancer and hepatic steatosis. ESMO Open 2021;6:100185. [PMID: 34139486 DOI: 10.1016/j.esmoop.2021.100185] [Reference Citation Analysis]
19 Wu M, Bai J, Ma C, Wei J, Du X. The Role of Gut Microbiota in Tumor Immunotherapy. J Immunol Res 2021;2021:5061570. [PMID: 34485534 DOI: 10.1155/2021/5061570] [Reference Citation Analysis]
20 Pan Y, Zhang X. Diet and gut microbiome in fatty liver and its associated liver cancer. J Gastroenterol Hepatol 2021. [PMID: 34664301 DOI: 10.1111/jgh.15713] [Reference Citation Analysis]
21 Song Q, Zhang X. The Role of Gut–Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC. Biomedicines 2022;10:524. [DOI: 10.3390/biomedicines10030524] [Reference Citation Analysis]
22 Li Y, Hou JJ, Wang X, Su S, Wang YM, Zhang J. New progress in research of intestinal microbiota in fatty liver disease. Shijie Huaren Xiaohua Zazhi 2021; 29(23): 1355-1361 [DOI: 10.11569/wcjd.v29.i23.1355] [Reference Citation Analysis]
23 Newsome RC, Yang Y, Jobin C. The microbiome, gastrointestinal cancer, and immunotherapy. J Gastroenterol Hepatol 2021. [PMID: 34820895 DOI: 10.1111/jgh.15742] [Reference Citation Analysis]
24 Xu H, Wang L. The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease. Front Mol Biosci 2021;8:792667. [PMID: 34901163 DOI: 10.3389/fmolb.2021.792667] [Reference Citation Analysis]
25 Ao H, Xin Z, Jian Z. Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma. Biomark Res 2021;9:91. [PMID: 34930486 DOI: 10.1186/s40364-021-00348-y] [Reference Citation Analysis]
26 Liao JX, Chen YW, Shih MK, Tain YL, Yeh YT, Chiu MH, Chang SKC, Hou CY. Resveratrol Butyrate Esters Inhibit BPA-Induced Liver Damage in Male Offspring Rats by Modulating Antioxidant Capacity and Gut Microbiota. Int J Mol Sci 2021;22:5273. [PMID: 34067838 DOI: 10.3390/ijms22105273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Paratore M, Santopaolo F, Cammarota G, Pompili M, Gasbarrini A, Ponziani FR. Fecal Microbiota Transplantation in Patients with HBV Infection or Other Chronic Liver Diseases: Update on Current Knowledge and Future Perspectives. J Clin Med 2021;10:2605. [PMID: 34204748 DOI: 10.3390/jcm10122605] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Cheng H, Ma K, Zhang L, Li G. The tumor microenvironment shapes the molecular characteristics of exhausted CD8+ T cells. Cancer Lett 2021;506:55-66. [PMID: 33662493 DOI: 10.1016/j.canlet.2021.02.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Mao J, Wang D, Long J, Yang X, Lin J, Song Y, Xie F, Xun Z, Wang Y, Wang Y, Li Y, Sun H, Xue J, Song Y, Zuo B, Zhang J, Bian J, Zhang T, Yang X, Zhang L, Sang X, Zhao H. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. J Immunother Cancer 2021;9:e003334. [PMID: 34873013 DOI: 10.1136/jitc-2021-003334] [Reference Citation Analysis]
30 Huang R, Wu E, Deng X. Potential of Lycium barbarum polysaccharide for the control of glucose and lipid metabolism disorders: a review. International Journal of Food Properties 2022;25:673-80. [DOI: 10.1080/10942912.2022.2057529] [Reference Citation Analysis]
31 Yang M, Khoukaz L, Qi X, Kimchi ET, Staveley-O'Carroll KF, Li G. Diet and Gut Microbiota Interaction-Derived Metabolites and Intrahepatic Immune Response in NAFLD Development and Treatment. Biomedicines 2021;9:1893. [PMID: 34944709 DOI: 10.3390/biomedicines9121893] [Reference Citation Analysis]
32 Foerster F, Gairing SJ, Müller L, Galle PR. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol 2021:S0168-8278(21)02037-7. [PMID: 34555422 DOI: 10.1016/j.jhep.2021.09.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Chen Y, Chen YX. Microbiota-Associated Metabolites and Related Immunoregulation in Colorectal Cancer. Cancers (Basel) 2021;13:4054. [PMID: 34439208 DOI: 10.3390/cancers13164054] [Reference Citation Analysis]
34 Han H, Jiang Y, Wang M, Melaku M, Liu L, Zhao Y, Everaert N, Yi B, Zhang H. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis. Crit Rev Food Sci Nutr 2021;:1-18. [PMID: 34404276 DOI: 10.1080/10408398.2021.1966738] [Reference Citation Analysis]
35 Li M, Rajani C, Zheng X, Jia W. The microbial metabolome in metabolic‐associated fatty liver disease. Journal of Gastroenterology and Hepatology. [DOI: 10.1111/jgh.15746] [Reference Citation Analysis]
36 Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani AL. Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC. Biomedicines 2021;9:1524. [PMID: 34829753 DOI: 10.3390/biomedicines9111524] [Reference Citation Analysis]